Lantern Pharma Inc. (LTRN) Stock Price & Analysis
Lantern Pharma Inc. (LTRN) — MoonshotScore 29/100 (Weak band), calculated Nov 18, 2026. Price $0.245 (-13.73%), as of the Nov 20, 2026 trading session; market cap $3.89M.
Educational signal · not a buy or sell recommendation · How to read this
Lantern Pharma Inc. · LTRN · NASDAQ
Lantern Pharma Inc. is a clinical-stage biotechnology company that leverages artificial intelligence and machine learning to accelerate drug development.
Price as of Nov 20, 2026
Key Statistics
MoonshotScore v2 · Lantern Pharma (LTRN)
WeakWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
Bottom-tier quality, a fragile balance sheet, weak growth and a full valuation, and the price trend has turned against it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Thin; Financial Safety: Fragile; Valuation: Full; Growth Durability: Fading; Momentum: Falling.
- EPS beat 0 of the last 4 reports
- Altman Z -23.73 · Piotroski F 1
Holding back: weak fundamentals, balance-sheet strain, weak price trend
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 27 | Weak | |
| 28 | Weak | |
| 28 | Weak | |
| 29 | Weak | |
| 29 | Weak | |
| 29 | Weak |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $0.245 | |
| Change on the day | -13.73% | |
| Market capitalisation | $3.89M | — |
| Shares traded on the day | 234.2K |
Price & events
Other perspectives
Council score for Lantern Pharma (LTRN): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
5 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Nov 19, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Nov 19, 2026, the Munger lens read the price at that time as undervalued against its own estimate of value.
Readings on this page are from Nov 21, 2026, except a card that shows its own read date.
What is Lantern Pharma (LTRN), and what does it report?
Short answer
A current FMP business description is unavailable; the listing and provider classification below are the available identity facts. Lantern Pharma Inc. (LTRN) is listed on NASDAQ. It employs 16 people. The market values it at $3.89M.
What do the latest results show for Lantern Pharma (LTRN)?
Short answer · as of
Against analyst estimates the company has EPS beat 0 of the last 4 reports.
What are the financial strengths and risks for Lantern Pharma (LTRN)?
Short answer
What is holding it back is weak fundamentals, balance-sheet strain, weak price trend. The distress and quality screens read Altman Z -23.73 · Piotroski F 1. Trailing ratios: ROA -93.1% · current ratio 1.49.
Data-derived red flags
- Listing risk — at $0.245 the shares sit below the $1.00 minimum bid NASDAQ requires for continued listing.
- Financial-distress signal — its Altman Z-Score of -23.73 sits in the distress zone (elevated bankruptcy risk).
- Inconsistent delivery — missed Wall Street EPS estimates in 0 of the last 4 reported quarters.
What should you watch next at Lantern Pharma (LTRN)?
Short answer · as of
Analyst estimates on file carry FY2026 revenue $1.95M · EPS -1.63 · 1 analysts.
What the records here don't tell us
- The next earnings date is not yet scheduled in the calendar we read.
- No quarterly income statement is held for LTRN.
Checked against the records this page reads, on the dates shown above.
How does Lantern Pharma compare with its peers?
Short answer
Lantern Pharma's score ranks 13th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
| Company | Price | Market value | Score |
|---|---|---|---|
| $13.45 Nov 19, 2026 | $475M | 91 5-pillar Nov 18, 2026 | |
| $9.07 Nov 19, 2026 | $540M | 91 5-pillar Nov 18, 2026 | |
| $2.90 Nov 20, 2026 | $245M | 90 5-pillar Nov 18, 2026 | |
| $41.19 Nov 19, 2026 | $776M | 88 5-pillar Nov 18, 2026 | |
| $15.52 Nov 19, 2026 | $86.9M | 82 5-pillar Nov 18, 2026 | |
| $11.17 Nov 19, 2026 | $102M | 82 5-pillar Nov 18, 2026 | |
| $3.69 Nov 19, 2026 | $160M | 72 5-pillar Nov 18, 2026 | |
| $1.84 Nov 20, 2026 | $174M | 69 5-pillar Nov 18, 2026 | |
| $11.54 Nov 20, 2026 | $817M | 69 5-pillar Nov 18, 2026 | |
| $9.28 Nov 19, 2026 | $545M | 68 5-pillar Nov 18, 2026 | |
| $30.43 Nov 20, 2026 | $1.02B | 64 5-pillar Nov 18, 2026 | |
| $7.98 Nov 20, 2026 | $780M | 63 5-pillar Nov 18, 2026 | |
| Lantern Pharma (LTRN) — this page | $0.245 | $3.89M | 29 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Revenue estimate
- $1.95M
- EPS estimate
- $-1.63
Measured against a quoted price of $0.245 (as of Nov 20, 2026).
Insider activity
Form 4 records via FMP · Most recent available transactions
- Transactions
- 12
- Identified insiders
- 4
- Purchases
- 2
- Sales
- 0
- Other transactions
- 10
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held LTRN in their latest 13F filing, and what they did against the filing before it.
None of the 16 tracked investors reported LTRN in their latest 13F filing.
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Lantern Pharma (LTRN)?
- Lantern Pharma Reports Third Quarter 2026 Financial Results and Provides Business Updates
- Lantern Pharma Announces Peer-Reviewed Publication of Phase 1a LP-184 Data in Recurrent Glioblastoma, Supporting a Phase 1b/2a Combination Trial with Spironolactone
- Lantern Pharma Inc. Schedules Third Quarter 2026 Financial Results Announcement
Common Questions About LTRN
These answers are editorial: 1 of these 9 answers is drawn from the LTRN research dossier (written May 10, 2026 by gemini-2.0-flash); the other 8 are question templates that restate figures shown above. Figures in this section are not part of the source register.
What does the MoonshotScore mean for LTRN?
LTRN carries the MoonshotScore stated above — the Weak band. This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Is LTRN a good stock to buy?
Stock Expert AI does not rate LTRN buy, sell or hold. Lantern Pharma Inc. carries a MoonshotScore, in the Weak band, a research rating against its peers rather than a forecast. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.
What is the LTRN stock price today?
The last price recorded for Lantern Pharma Inc. (LTRN), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What do analysts say about LTRN stock?
Analyst coverage of Lantern Pharma Inc. is limited, reflecting its small market capitalization and early stage of development. However, analysts generally view the company's AI-driven approach to drug discovery as a potential differentiator in the competitive biotechnology landscape.
What are the key factors to evaluate for LTRN?
Lantern Pharma Inc. (LTRN) holds a MoonshotScore in the low range. The RADR AI platform analyzes molecular data to identify patient populations most likely to respond to specific therapies, increasing the probability of clinical trial success. Not financial advice.
How frequently does LTRN data refresh on this page?
LTRN's price is the last quote we recorded, from the Nov 20, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.
What has driven LTRN's recent stock price performance?
Lantern Pharma Inc. (LTRN) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary AI platform (RADR). See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider LTRN overvalued or undervalued right now?
Lantern Pharma Inc. (LTRN) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of LTRN?
Fractional-share availability for Lantern Pharma Inc. (LTRN) depends on your brokerage, account and supported securities. Check the broker's current eligibility, minimums and fees before placing an order.
Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated May 10, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 14 figures on this page — 7 from Financial Modeling Prep (FMP), 6 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com